Olfactory Cleft Obstruction and Electrophysiological Field Potentials Predict Olfactory Restoration by Dupilumab in CRSwNP Patients.
Olfactory Cleft Obstruction and Electrophysiological Olfactory Bulb Generated Beta Field Potentials Predict Olfactory Restoration by Dupilumab in CRSwNP Patients.
Who can join
Ages 18 to 65 · All sexes
Full eligibility criteria
* Well documented history of CRSwNP * BSIT age/sex classified as "abnormal" score * Self-reported stable olfactory deficit of moderate to severe quality \> 3 months * Prior endoscopic sinus surgery \>3 months, \<10 years prior
About the study
The goal of this observational study is to learn what can predict the return of the sense of smell in patients with chronic rhinosinusitis with nasal polyps being treated with dupilumab. The main questions it aims to answer are:
1. Does obstruction of the olfactory cleft predict return of the sense of smell? 2. Do electrophysiological signals generated by breathing and sniffing behavior predict return of the sense of smell?
Participants starting dupilumab will undergo assessment for their degree of olfactory cleft obstruction, and an electrophysiologic assessment of their olfactory cleft and be followed over 6 months of treatment with dupilumab.
What is being tested
- Dupilumab - Standard Dose (drug)
Sponsor: Northwestern University · Participants: 30 · Started: May 1, 2025
Contact the study team
- Clinical Coordinator · Phone: 312 6958182
- Bruce Tan, MD · Phone: 312 6958182
Official record on ClinicalTrials.gov — NCT06892704
Locations in the U.S.
| Illinois | Northwestern University Feinberg School of Medicine, Chicago |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.